Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.62 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.62 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | IL1B | P01584 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PDE6D | O43924 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9988681 | 0.90 | DDB1 (0.60) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL19370936 | 0.89 | CRBN (0.49) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21062845 | 0.86 | CRBN (0.60) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21196697 | 0.86 | DDB1 (0.60) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL32679446 | 0.86 | CRBN (0.60) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL3797637 | 0.86 | DDB1 (0.60) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL22649626 | 0.85 | DDB1 (0.48) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL12041893 | 0.85 | CRBN (0.53) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL845548 | 0.84 | CRBN (0.54) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24744448 | 0.84 | DDB1 (0.49) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024108009-A1 | DYRK/CLK PROTACS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023249968-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-DJPYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230159559-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2023088245-A1 | DEGRADATION AGENT AND USE THEREOF | 成都先导药物开发股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2022068849-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEIGENE, LTD. (KY) | 2022-04-07 | — | — | WO | disclosed |
| WO-2021018018-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159559-A1 | COMPOUND FOR INHIBITING AND INDUCING DEGRADATION OF EGFR KINASE | EGFR, ERBB2, ERBB3 | CRBN 898/4885DDB1 2765/4885IKZF3 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.